A Ludwig Cancer Research study has discovered that recurrent tumors of the aggressive brain cancer glioblastoma multiforme (GBM) grow out of the fibrous scars of malignant predecessors destroyed by interventions such as radiotherapy, surgery and immunotherapy.
A Ludwig Cancer Research study has identified a metabolic switch in the immune system’s T cells that is essential to the generation of memory T cells—which confer lasting immunity to previously encountered pathogens—and a T cell subtype found in tumors that drives anti-tumor responses during immunotherapy.
A novel immunotherapy approach developed by Ludwig Cancer Research scientists employs a two-pronged attack against solid tumors to boost the immune system’s ability to target and eliminate cancer cells.
Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies.
A Ludwig Cancer Research study has discovered how a lipid molecule found at high levels within tumors undermines the anti-cancer immune response and compromises a recently approved immunotherapy known as adoptive cell therapy (ACT) using tumor infiltrating lymphocytes, or TIL-ACT.
Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting conditions in tumors that predict whether such patients are likely to respond to a personalized immunotherapy known as adoptive T cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL).
It is with great pleasure that we announce the appointment of Lydia Lynch as a full member of the Princeton Branch of the Ludwig Institute for Cancer Research.
A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy brain tissue, illuminating how they help shape the internal environment of tumors to support cancer growth and immune evasion.
Ludwig Cancer Research announces its launch of the Ludwig Leadership Fellows Program, which aims to accelerate the careers of exceptional young scientists by helping them establish genuinely independent programs of research immediately after the completion of their graduate studies.
A Ludwig Cancer Research study has for the first time exhaustively analyzed neutrophils that reside in brain tumors, detailing how the immune cells support brain cancer survival and how they’re turned by the tumor microenvironment into enablers of malignant growth.
A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.
In exploring an aspect of how killer T cells generate the raw materials required for their proliferation, a Ludwig Cancer Research study has uncovered an unexpected link between the immune cells’ metabolism, regulation of gene expression, persistence and functional efficacy that could be exploited using existing drugs to improve cancer immunotherapy.
A Ludwig Cancer Research study has identified a pair of genes whose expression by a type of immune cell within tumors is predictive of outcomes for cancer patients and is linked to a vast network of gene expression programs, engaged by multiple cell types in the tumor microenvironment, that control human cancers.
A Ludwig Cancer Research study has discovered that the presence of relatively high numbers of immune cells known as monocytes in tumors is linked to better outcomes in esophageal cancer patients treated with a combination of chemotherapy and immunotherapy, or immunochemotherapy.
Researchers at the Ludwig Center at Harvard have developed a platform technology for imaging that enables integration of the methods of microscopic analysis long employed in pathology laboratories with the visualization of multiple molecular markers in individual cells that is now rapidly advancing in research labs.
Ludwig Cancer Research congratulates Douglas Hanahan, Ludwig Distinguished Scholar at the Lausanne Branch of the Ludwig Institute for Cancer Research, on his election as Foreign Member of the Royal Society.
Two independent Ludwig Cancer Research studies published in the current issue of the journal Cell show that immune cells known as neutrophils, whose abundance in the microenvironment of tumors has traditionally been associated with poor patient prognosis, can play an important role in the success of cancer immunotherapies.
It is with great pleasure that we announce the appointment of Jedd Wolchok and Nicolas Killen to the Board of Directors of the Ludwig Institute for Cancer Research and the LICR Fund, which manages the assets of the Institute.
A Ludwig Cancer Research study has discovered that the immune system’s surveillance of cancer can itself induce metabolic adaptations in the cells of early-stage tumors that simultaneously promote their growth and equip them to suppress lethal immune responses.
A Ludwig Cancer Research study has revealed a single protein expressed at high levels by cancer cells across a broad range of malignancies that erects a multifaceted barrier to anti-cancer immune responses in mouse models of cancer and so shields tumors from immune detection and destruction.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right